Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGT-2168 vs Clopidogrel for GI Event Reduction in ACS/CAD
NCT00557921Phase 3Terminated
- Sponsor
- Cogentus Pharmaceuticals
- Start
- Dec 2007
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of clopidogrel and omeprazole in acute coronary syndrome (ACS), myocardial infarction (MI) and coronary artery disease (CAD) (2 arms), sponsored by Cogentus Pharmaceuticals. Primary endpoint: Composite of upper gastrointestinal clinical events at 48 weeks. Started Dec 2007; status: terminated.
02
Drugs
clopidogrelomeprazole
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00557921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557921.